Sousa Isabel Oliveira de, Diniz Erik Trovão, Marques Thyciara Fontenele, Griz Luiz, Coutinho Mário de Almeida Pereira, Bandeira Francisco
Hospital Agamenon Magalhães, Universidade de Pernambuco, Recife, PE, Brasil.
Arq Bras Endocrinol Metabol. 2010 Mar;54(2):244-9. doi: 10.1590/s0004-27302010000200023.
To evaluate the responses of serum beta-CTX and osteocalcin in patients who were undergoing treatment with teriparatide or strontium ranelate (SR).
We analyzed 14 patients (12 women and 2 men; mean age of 71 years) taking teriparatide, and 13 female patients (mean age of 70 years) taking SR; all the patients having previously been on bisphosphonates. Serum beta-CTX and osteocalcin levels were determined before and after the first and third months of teriparatide treatment and up to the fourth month of treatment with SR.
We observed an initial significant increase in osteocalcin levels during the first month (165%, p = 0.01) followed by a peak of beta-CTX (180%, p = 0.02) after the third month of treatment with teriparatide. An increase in these markers was also observed with SR: 49% in osteocalcin (p = 0.002) and 80% in beta-CTX (p = 0.008).
SR had a predominantly short-term bone-forming effect in postmenopausal women with osteoporosis previously treated with bisphosphonates in a lesser degree than with teriparatide.
评估接受特立帕肽或雷奈酸锶(SR)治疗的患者血清β-CTX和骨钙素的反应。
我们分析了14例接受特立帕肽治疗的患者(12名女性和2名男性;平均年龄71岁)以及13例接受SR治疗的女性患者(平均年龄70岁);所有患者此前均接受过双膦酸盐治疗。在特立帕肽治疗的第一个月和第三个月前后以及SR治疗至第四个月时测定血清β-CTX和骨钙素水平。
我们观察到在特立帕肽治疗的第一个月骨钙素水平最初显著升高(165%,p = 0.01),随后在第三个月β-CTX达到峰值(180%,p = 0.02)。使用SR时这些标志物也出现升高:骨钙素升高49%(p = 0.002),β-CTX升高80%(p = 0.008)。
在既往接受过双膦酸盐治疗的绝经后骨质疏松症女性中,SR的主要作用是短期成骨,其程度低于特立帕肽。